Abbvie

This early-phase study tested an experimental drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had stopped responding to treatment. The main goals were to find a safe dose and see if the drug …

This study looked at the long-term safety of cariprazine in 310 children with schizophrenia, bipolar I disorder, or autism spectrum disorder over 52 weeks. The main goal was to track side effects and changes in health measures like lab tests, vital signs, and movement disorders. …

This early-phase study tested an experimental drug called ABBV-CLS-579, alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapies. The main goals were to find safe doses and measure how the drug moves through…

This study tested a daily pill called upadacitinib in 642 adults with active psoriatic arthritis who had not gotten enough relief from biologic drugs. Participants received either 15 mg, 30 mg of upadacitinib, or a placebo for 12 weeks. The main goal was to see if the drug reduce…

This study looked at 14 people with chronic lymphocytic leukemia (CLL) who were taking the drug Venetoclax for the first time as part of their normal treatment. The goal was to see how safe the drug is and how well it works in everyday medical practice. The study did not test a n…

This study tested whether adding the drug venetoclax to a mild chemotherapy (low-dose cytarabine) helps adults with acute myeloid leukemia (AML) live longer. The trial included 211 people aged 75+ or 18-74 with health issues that made strong chemo too risky. Results showed that t…

This study looked at how well the drug venetoclax works for adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. About 120 people in Switzerland and Austria took venetoclax pills daily as part of their normal care. Researche…

This study tested whether a combination of two drugs, venetoclax and azacitidine, can help keep acute myeloid leukemia (AML) from returning after patients achieve remission with standard chemotherapy. It involved 112 adults with AML who were in their first remission. The goal was…

This study looked at how safe and effective upadacitinib (RINVOQ) is for Korean adults with moderate to severe ulcerative colitis or Crohn's disease. About 600 patients took the drug as prescribed by their doctor and were followed for up to 52 weeks. The main goal was to track an…

This study looked at how safe and effective the drug risankizumab (brand name Skyrizi) is for adults with moderate to severe plaque psoriasis or psoriatic arthritis. Over 2,300 participants in Korea received the drug as prescribed by their doctor for 52 weeks. Researchers tracked…

This study looked at the safety and effectiveness of upadacitinib, a drug already approved for eczema, in 167 teenagers aged 12 to 18 in Japan. Researchers tracked side effects and how well the drug worked over 2 years in everyday medical practice. The goal was to confirm the dru…

This study tested an experimental drug called elezanumab in 121 people who had a recent stroke. The goal was to see if the drug could improve brain function and reduce disability compared to a placebo. Participants received the drug or placebo by IV within 24 hours of their strok…

This study checked the safety and how well the drug upadacitinib works in over 2300 Korean patients with rheumatoid arthritis, atopic dermatitis, ankylosing spondylitis, or psoriatic arthritis. Patients took the drug as prescribed by their doctor and were followed for about 28 we…

This study tested an experimental drug called ABBV-916 in people with early Alzheimer's disease. The goal was to see if it is safe and can slow down the disease. About 106 adults aged 50-90 took part. They received either the drug or a placebo by IV every 4 weeks for 6 months, wi…

This early-stage study tested a single injection of RST-001 into the eye for people with advanced retinitis pigmentosa, a genetic condition causing severe vision loss. All 14 participants had very poor vision (hand motion or worse). The main goal was to check safety, and the trea…

This study tested an experimental drug called ABBV-668 in about 30 adults with moderate to severe ulcerative colitis, a condition causing inflammation and bleeding in the colon. Participants took the drug twice daily for 16 weeks. The goal was to see if it could improve colon hea…

This study compared two approved medications, risankizumab (injections every 12 weeks) and deucravacitinib (daily pills), in 393 adults with moderate plaque psoriasis. The goal was to see which treatment better clears skin and reduces symptoms. Participants were not previously tr…

This phase 2 study tested a drug called mirvetuximab soravtansine in 79 people with recurrent ovarian, peritoneal, or fallopian tube cancer that had high levels of a protein called folate receptor-alpha. The cancer had come back after platinum-based chemotherapy but was still sen…

This study tested an oral medication called upadacitinib in 912 teenagers and adults with moderate to severe eczema (atopic dermatitis) that was not well controlled with creams. The goal was to see if the drug could significantly clear the skin rash and reduce itching compared to…

This study looked at the safety of a continuous 24-hour infusion of ABBV-951, a drug given under the skin, for people with advanced Parkinson's disease. It included 130 adults who had already completed a previous study with the same drug. The main goal was to check for side effec…

This study tested whether adding the experimental drug venetoclax to standard azacitidine works better than azacitidine alone for adults with untreated acute myeloid leukemia (AML) who cannot handle strong chemotherapy. About 443 participants received either the combination or a …

This study looked at how well risankizumab works compared to other biologic drugs for adults with moderate to severe plaque psoriasis. About 2,759 participants were followed to see how many achieved significant skin clearance and how long they stayed on their treatment. The goal …

This study looked at how safe and effective the drug venetoclax is for people with acute myeloid leukemia (AML), a rare and aggressive blood cancer. About 150 adults in South Korea took venetoclax pills as part of their normal treatment. Researchers tracked side effects and how w…

This study looked at the long-term safety of a daily pill called atogepant for preventing migraines in people with chronic or episodic migraine. About 596 adults who had already completed a previous atogepant study took the drug for up to 156 weeks (about 3 years). The main goal …

This study tested a gel stent implant placed outside the eye to lower pressure in people with open-angle glaucoma. 74 adults aged 45 and older took part and were followed for 12 months. The goal was to see if the stent safely reduces eye pressure by at least 20% with the same or …

This study tested the long-term safety and effectiveness of tavapadon, an experimental drug for Parkinson's disease. Nearly 1,000 participants took flexible doses of the medication for 58 weeks. Researchers monitored side effects, symptom changes, and quality of life to see if th…

This study followed 156 people in China with moderate-to-severe Crohn's disease who were prescribed Humira (adalimumab) by their doctors. Researchers tracked serious side effects and how well the drug controlled disease activity over one year. The goal was to see how Humira works…

This study looked at how safe and effective the drug Rinvoq is for adults with moderate to severe ulcerative colitis (UC), a chronic inflammatory bowel disease. About 300 participants in Japan took Rinvoq as prescribed by their doctor and were followed for up to 60 weeks. The mai…

This study tested a drug called upadacitinib in 429 people with giant cell arteritis, a condition that causes inflamed arteries. The goal was to see if the drug could help patients achieve remission while using steroids for a shorter time. Results showed that upadacitinib combine…

This study tested a daily pill called upadacitinib in 734 adults with axial spondyloarthritis, a type of arthritis that causes back pain and stiffness. The goal was to see if the drug reduces symptoms better than a placebo. Participants took the drug or a placebo for 14 weeks, an…

This study looked at how safe and effective the drug RINVOQ is for adults with ankylosing spondylitis, a type of arthritis that mainly affects the spine. About 69 people in Japan took RINVOQ as prescribed by their doctor and were followed for up to a year. The goal was to track s…

This study looked at 240 adults in Taiwan with moderate to severe plaque psoriasis, a chronic skin condition causing red, scaly patches. Researchers compared the drug risankizumab to other biologic treatments to see how long it keeps skin clear. Participants were followed for abo…

This study looked at how well the drug upadacitinib works in real life to quickly and steadily reduce pain in people with axial spondylarthritis, a type of arthritis that mainly affects the spine. About 650 adults with active disease took the pill as prescribed by their doctor an…

This study tested an experimental drug called elezanumab in people with a recent cervical spinal cord injury. The goal was to see if the drug could improve arm and hand movement and was safe. About 60 adults aged 18-75 with severe neck-level injuries received either the drug or a…

This study tested a drug called navitoclax, either alone or added to the standard treatment ruxolitinib, in 191 people with a bone marrow cancer called myelofibrosis. The main goal was to see if the treatment could shrink an enlarged spleen by at least 35% after 24 weeks. The stu…

This study tested the long-term safety of adalimumab (a drug that blocks inflammation) in 59 children with ulcerative colitis who had already completed a previous study. Researchers tracked side effects and how well the drug controlled disease symptoms using standard scoring tool…

This study tests whether adding the experimental drug navitoclax to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 252 adults with myelofibrosis took part. The main goal was to see if the combo …

This study tested a daily pill called upadacitinib in over 900 teens and adults with moderate to severe eczema (atopic dermatitis) who needed stronger treatment. The goal was to see if the drug could clear skin and reduce itching better than a placebo. Results showed significant …

This study followed about 400 Canadian adults with moderate to severe rheumatoid arthritis who were prescribed upadacitinib by their doctors. Researchers measured how well the drug controlled disease activity and symptoms like pain and stiffness over 24 months. The goal was to se…

This study tested two drug combinations (venetoclax plus obinutuzumab or ibrutinib) in 20 Japanese adults with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how well the treatments worked and if they were safe. Participants …

This study tested a daily pill called upadacitinib in 1,705 adults with active psoriatic arthritis who had not gotten enough relief from standard non-biologic drugs. The goal was to see if it reduced joint pain and swelling better than a placebo or an injected biologic (adalimuma…

This study tested whether JUVÉDERM VOLITE, a gel injected into the skin, can safely improve neck lines in Chinese adults. About 159 participants with moderate to severe neck wrinkles received either the gel or no treatment. The goal was to see if the gel reduces wrinkle severity …

This study tested the drug risankizumab (Skyrizi) in 214 adults with moderate to severe psoriasis on the genitals or scalp. Participants received either the drug or a placebo for 16 weeks, then all received the drug. The goal was to see if the drug could clear or nearly clear the…

This study tested whether BOTOX injections can safely and effectively reduce the width of the lower face caused by large masseter (chewing) muscles. About 200 adults with noticeable masseter muscle prominence received either BOTOX or a placebo injection into both sides of the jaw…

This study followed about 200 adults in Israel who were prescribed ubrogepant or atogepant for migraines. Researchers wanted to see how satisfied people were with these drugs in everyday use. Participants took the medication as their doctor ordered and reported their satisfaction…

This study tested a drug called linaclotide in children aged 2 to 5 years with functional constipation (difficulty passing stool). About 123 children received either the drug or a placebo for 12 weeks, followed by 24 weeks where everyone got the drug. The goal was to see if the d…

This study tested whether JUVÉDERM® VOLITE™, an injectable gel, can improve skin quality like hydration and radiance in adults with fine lines and wrinkles. About 135 participants in China were randomly assigned to receive the gel or no treatment. The study measured skin improvem…

This study tested a new medicine called CVL-231 (Emraclidine) in 391 adults with schizophrenia who were having a sudden worsening of psychotic symptoms. The goal was to see if the drug could reduce symptoms like hallucinations and delusions better than a placebo over 6 weeks. Par…

This study tested a new injection called AGN-151586 for treating moderate to severe frown lines between the eyebrows. About 300 adults who had never used botulinum toxin before received either the study drug or a placebo. The goal was to see if the treatment safely reduces frown …

This study tested whether BOTOX injections can safely reduce the size of the masseter muscle, the chewing muscle that can make the lower face look wide. About 200 adults with noticeable jaw muscle bulk received either BOTOX or a placebo. The results showed that BOTOX improved the…

This study tested a new medication called tavapadon in 304 people with early Parkinson's disease. The goal was to see if it could improve movement and daily activities better than a placebo over 27 weeks. Tavapadon is designed to help control symptoms, not cure the disease.

This study tested whether BOTOX injections can make a wide, square jaw look slimmer by relaxing the chewing muscle. About 249 adults with prominent jaw muscles received either BOTOX or a placebo. The main goal was to see if the jaw appearance improved by at least two grades on a …

This early-stage study tested whether combining a new drug (AGN-151586) with BOTOX is safe for treating moderate to severe frown lines between the eyebrows. 132 healthy adults received a single treatment and were monitored for side effects and immune reactions. The goal was to ch…

This study looked at how satisfied people were with the look of their face and neck after getting a combination of cosmetic treatments like Botox, fillers, and skin products. It included 130 adults with different skin types and backgrounds. The goal was to see if these treatments…

This study looked at how satisfied adults were after getting BOTOX for frown lines, crow's feet, and forehead lines. About 100 people with moderate to severe lines received injections and filled out questionnaires. The main goal was to see how many felt 'mostly satisfied' or 'ver…

This study looked at the long-term safety of the drug linaclotide in children aged 6 to 17 who have either functional constipation or irritable bowel syndrome with constipation (IBS-C). A total of 381 children who had already completed earlier studies took the medicine for up to …

This study looked at how well the drug upadacitinib works for people with moderate to severe eczema who also have hard, itchy bumps called prurigo nodularis. About 200 adults and teens in Japan took a daily pill for 48 weeks. The main goal was to see if their worst itch got much …

This study tested a purified botulinum toxin (onabotulinumtoxinA) to treat moderate to severe forehead lines in about 150 Japanese adults. Participants received injections or a placebo and were followed for up to 12 months. The goal was to see if the treatment safely reduces wrin…

This study followed 120 adults with bipolar I disorder who were starting cariprazine (Vraylar) for a major depressive episode. Researchers measured changes in depression symptoms, daily functioning, and quality of life over 24 weeks in real-world clinic settings. The goal was to …

This study tested a new drug called CVL-231 (Emraclidine) in 385 people with schizophrenia who were having a sudden worsening of psychotic symptoms. Participants took either a low dose, a high dose, or a placebo daily for 6 weeks. The main goal was to see if the drug reduced symp…

This study tested whether BOTOX injections can reduce hand tremors and make daily tasks like eating and writing easier. About 174 adults with upper limb essential tremor received either BOTOX or a placebo. Researchers measured changes in tremor-related disability and tracked side…

This study tested an experimental drug called ABBV-552 in people with mild Alzheimer's disease. The goal was to see if it is safe and can help with memory and thinking problems. About 263 adults aged 50 to 90 took a daily pill or a placebo for 12 weeks. Researchers measured chang…

This study tested a drug called linaclotide in 19 babies and toddlers (6 months to under 2 years old) with functional constipation, a common condition with no approved medicines for this age group. The drug is already approved for adults and older children. The study measured how…

This study tested an experimental drug called ABBV-932 in 161 adults with bipolar I or II disorder who were currently experiencing a depressive episode. Participants took either the drug or a placebo daily for 6 weeks to see if it safely improves mood and reduces depression sympt…

This study tested a new injectable filler, JUVÉDERM® VOLITE™, to safely and effectively reduce lines around the mouth in Chinese adults. About 198 participants were split into two groups: one received the filler, and the other received no treatment but could get it after two mont…

This study tested a new injectable filler called HAC 22L to improve volume loss in the midface area (cheeks) due to aging. About 75 adults who wanted cheek enhancement were randomly assigned to get the filler right away or wait 6 months. The results showed the filler safely impro…

This early-stage study tested the safety and how the body handles ABBV-932, an oral drug, in 20 healthy Chinese adults. Participants took multiple doses to see how the drug moves through the body and if it causes side effects. The goal was to gather information, not to treat any …

This study aimed to understand how vitiligo affects people's daily lives and healthcare use in China. Researchers observed 100 patients aged 12 and older with non-segmental vitiligo, measuring skin involvement and quality of life through questionnaires. The goal was to capture th…

This study tested how well the drug risankizumab enters the body when given through a wearable injector compared to a standard syringe. It involved 260 healthy adults and measured drug levels in the blood and any side effects. The goal was to see if the new device works as well a…

This study looked at how a new tablet form of the drug venetoclax is absorbed by the body in 72 healthy female volunteers. Researchers compared the new tablet to the current commercial version and also checked if taking it with a high-fat meal changed absorption. The goal was to …

This study looked at the safety of the drug RINVOQ in over 4,000 Japanese adults with rheumatoid arthritis, a condition that causes joint pain and swelling. Researchers monitored medical records for serious infections and other side effects over three years. No extra tests were d…

This study tested a new drug called ABBV-142 in 73 healthy adults to see if it is safe and how the body handles it. Participants received a single dose, and researchers monitored side effects and drug levels in the blood. The goal was to gather early safety information, not to tr…

This study tested how well risankizumab enters the body when given by a prefilled pen compared to a traditional syringe. It involved 59 healthy adults and measured drug levels, side effects, and immune response. The goal was to see if the pen works as well as the syringe, which c…

This study looked at how much of the drug risankizumab passes into breast milk of women with inflammatory bowel disease (IBD). About 10 breastfeeding women who were already taking risankizumab provided milk samples. The goal was to measure drug levels and check for any side effec…

This study looked at how a high-fat meal changes the way ABBV-101 moves through the body. Seventeen healthy adults took the drug by mouth, and researchers measured its levels in the blood. The goal was to understand food's impact, not to treat any disease. Results help guide futu…

This study involved 263 healthy adults to see how well the drug risankizumab is absorbed when given through a wearable on-body injector compared to a standard injection. The goal was to measure drug levels in the blood and check for side effects. No treatment benefit was expected…

This study tracked 89 Japanese adults with chronic lymphocytic leukemia (CLL) who took venetoclax, sometimes with rituximab, for 24 months. Researchers measured how many patients had undetectable minimal residual disease (uMRD), a sign of deep remission. The goal was to understan…

This early-stage study tested the safety and tolerability of a new drug called GUB014295 in 76 healthy adults who were lean, overweight, or obese. Participants received either the drug or a placebo as a single or multiple doses under the skin. The main goal was to check for side …

This study looked at how a tablet form of the experimental drug ABBV-722 moves through the body in 11 healthy adults. Researchers measured drug levels in the blood and checked if taking it with food changes absorption. The goal was to gather basic safety and processing informatio…

This early-stage study tested the safety and tolerability of a new drug called ABBV-8736 in 24 healthy adult volunteers. Participants received multiple doses of the drug or a placebo to see how the body processes it and whether it causes side effects. The goal was not to treat an…

This early-stage study tested the safety and how the body processes a new drug called ABBV-CLS-616 in 110 healthy volunteers. Participants took single or multiple doses of the drug to check for side effects and how it interacts with food or other medicines. The goal was to gather…

This study tested a new questionnaire called DermCLCI-p to see if it accurately measures the long-term life impacts of moderate-to-severe psoriasis. 154 adults starting a standard treatment (risankizumab) filled out the questionnaire over 28 weeks. The goal was to validate the to…

This study looked at how the experimental drug ABBV-1354 moves through and leaves the body in 8 healthy adult men. Participants took a single dose containing a tiny radioactive marker so scientists could measure the drug in blood, urine, and stool. The goal was to understand the …